Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria by Tang et al
We appreciate the comments by Tang et al1 in response to the publication of the 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) antiphospholipid syndrome (APS) classification criteria.2 3 We were interested to read about their study describing the performance of the classification criteria in 965 potential APS patients of Asian descent in China. Compared with their ‘gold standard’ involving clinical assessment of each potential APS case by two experienced rheumatologists, the authors report a specificity of 98% (95% confidence interval (CI) 97% to 99%) and se...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Barbhaiya, M., Zuily, S., Hendry, A. M., Manneville, F., Guillemin, F., Costenbader, K. H., Erkan, D. Tags: ARD Correspondence response Source Type: research
Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria
The release of the eagerly anticipated 2023 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Antiphospholipid Syndrome (APS) Classification Criteria1 marks a significant milestone since the revision of the Sapporo criteria in 2006.2 The updated criteria, characterised by a compulsory entry requirement and the application of an additive weighted system, have been rigorously validated in two distinct cohorts, demonstrating a remarkable specificity of 99% and a commendable sensitivity of 84%. To ensure comprehensive validation across diverse ethnic groups, we conducted a study involving 965 po...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Tang, Z., Shi, H., Liu, H.-L., Cheng, X., Ye, J., Su, Y., Hu, Q., Meng, J., Pan, H., Yang, C., Teng, J., Liu, T. Tags: ARD Correspondence Source Type: research
Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria by Miro-Mur et al
We appreciate the comments by Miro-Mur et al1 in response to the publication of 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Antiphospholipid Syndrome (APS) classification criteria.2 3 The authors discuss the challenge of establishing thresholds to define ‘moderate’ (40–79 U) and ‘high’ (>80 U) level anticardiolipin antibody (aCL) and anti-β2-glycoprotein-I antibody (aβ2GPI), which are required laboratory parameters of the new classification system. We also note their concern that ELISA tests are ‘advocated’, whil...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Erkan, D., Barbhaiya, M., Zuily, S., Bertolaccini, M. L., Willis, R., Devreese, K. Tags: ARD Correspondence response Source Type: research
Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria
The following considerations are a response to the recently published 2023 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) antiphospholipid syndrome (APS) classification criteria by the steering committee on the APS from the ACR and EULAR.1 2 These updated criteria present an improvement from the Sapporo-modified classification criteria for APS, otherwise known as the Sydney’s classification criteria.3 Manifestly, the new criteria aim to classify APS patients with heightened specificity, up to 99%, to better investigate the underlying mechanisms of this autoimmune dis...
Source: Annals of the Rheumatic Diseases - February 15, 2024 Category: Rheumatology Authors: Miro-Mur, F. A., Alijotas-Reig, J., Anunciacion-Llunell, A., Marques-Soares, J., Esteve-Valverde, E., Pardos-Gea, J. Tags: ARD Correspondence Source Type: research
IgM antibodies against acetylated proteins as a possible starting point of the anti-modified protein antibody response in rheumatoid arthritis
Rheumatoid arthritis (RA) is characterised by the presence of anti-modified protein antibodies (AMPA): anti-citrullinated protein antibodies (ACPA), anti-carbamylated protein antibodies (anti-CarP) and anti-acetylated protein antibodies (AAPA). These AMPA responses are specific for RA and have consistently been found to develop years before disease onset.1 2 Most studies on AMPA in (pre-disease) RA are focused on IgG antibodies. However, IgM is the first isotype generated in (auto)antibody responses. It is unclear whether IgM autoimmunity differs between AMPA targeting different post-translational modifications (PTMs). Sin...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: van Wesemael, T. J., Reijm, S., Kawakami, A., Dorjee, A. L., Stoeken, G., Maeda, T., Kawashiri, S.-y., Huizinga, T. W. J., Tamai, M., Toes, R. E. M., van der Woude, D. Tags: ARD Letter Source Type: research
IL-17A inhibitor-induced leucocytoclastic vasculitis is responsive to IL-23 blockade in a psoriatic arthritis patient
Introduction Secukinumab is a fully humanised monoclonal antibody directed at interleukin 17A (IL-17A) which has been widely used for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis.1 The use of secukinumab increases the risk of mucocutaneous candidiasis, but little is known about other specific cutaneous adverse events (AEs). Of note, few cases of secukinumab-induced leucocytoclastic vasculitis (LCV) have been described in the literature.2 3 Case presentation A 59-year-old man with a history of plaque psoriasis and PsA refractory to first-line and second-line treatment presented wit...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Binod, K., Jabbour, A., Poudel, P., Banki, K., Perl, A. Tags: ARD Letter Source Type: research
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis
Advanced targeted therapies including tumour necrosis factor inhibitors (TNFis) have transformed the clinical management of rheumatoid arthritis (RA). However, monoclonal antibody (MAb)-derived TNFis are associated with development of immunogenicity resulting in low circulating drug levels ().1 A genetic predictor of immunogenicity would have clinical utility by providing a pretreatment biomarker that could be used to inform therapy selection. Previous genetic studies of TNFi immunogenicity have focused on alleles within the HLA locus on chromosome 6.2–4 Patients were followed for 12 months with serum samples collect...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Yap, C. F., Nair, N., de Vries, A., Loeff, F. C., Morgan, A. W., Isaacs, J. D., Wilson, A. G., Hyrich, K. L., Barton, A., Plant, D. Tags: Open access, ARD Letter Source Type: research
Frosted branch angiitis in systemic lupus erythematosus
A young Asian Indian woman came with sudden blurring of vision in both eyes for 6 days. The best-corrected visual acuity in the right eye was counting fingers and in the left eye was 20/200. External examination showed the characteristic appearance of a butterfly rash on her face. The slit lamp examination was unremarkable. Fundus examination showed retinal vasculitis with characteristic perivascular infiltration giving the appearance of frosted branches along with perivascular haemorrhages in both eyes (figure 1). Optical coherence tomography scan showed the presence of macular oedema along with hyper-reflectivity of inne...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Chauhan, K., Kiri, H., Tyagi, M. Tags: ARD, Images in rheumatology Source Type: research
Ultra-rare genetic variation in relapsing polychondritis: a whole-exome sequencing study
Conclusions
This study identified specific rare variants in the DCBLD2 gene as a putative genetic risk factor for RP. These findings should be validated in additional patients with RP and supported by future functional experiments. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Luo, Y., Ferrada, M. A., Sikora, K. A., Rankin, C., Alessi, H. D., Kastner, D. L., Deng, Z., Zhang, M., Merkel, P. A., Kraus, V. B., Allen, A. S., Grayson, P. C. Tags: ARD, Miscellaneous Source Type: research
Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping
Conclusion
Cohort-wide and cross-disease immunophenotyping elucidate clinically heterogeneous patient subtypes existing within single disease in immune cell type-specific manner. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Tanaka, H., Okada, Y., Nakayamada, S., Miyazaki, Y., Sonehara, K., Namba, S., Honda, S., Shirai, Y., Yamamoto, K., Kubo, S., Ikari, K., Harigai, M., Sonomoto, K., Tanaka, Y. Tags: Open access, ARD, Autoimmunity Source Type: research
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials
Conclusions
According to these results, it appears that the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Also, extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen. However, as this study was underpowered to make this comparison, further prospective studies are needed to determine the potential long-term benefits of extending treatment in these patients. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Delestre, F., Charles, P., Karras, A., Pagnoux, C., Neel, A., Cohen, P., Aumaitre, O., Faguer, S., Gobert, P., Maurier, F., Samson, M., Godmer, P., Bonnotte, B., Cottin, V., Hanrotel-Saliou, C., Le Gallou, T., Carron, P.-L., Desmurs-Clavel, H., Direz, G., Tags: Editor's choice, ARD Lay summaries, ARD, Vasculitis Source Type: research
Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial
Conclusions
These data suggest that in patients with ANCA-associated vasculitis receiving rituximab, efficacy of treatment with avacopan compared with a prednisone taper was similar at week 26 and greater at week 52, with a favourable safety profile. In addition, avacopan was associated with improved renal outcomes and lower glucocorticoid toxicity. These results demonstrate the efficacy and safety of avacopan in patients receiving background induction therapy with rituximab.
Trial registration number
NCT02994927. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Geetha, D., Dua, A., Yue, H., Springer, J., Salvarani, C., Jayne, D., Merkel, P., ADVOCATE Study Group, Au Peh, Chakera, Cooper, Kurtkoti, Langguth, Levidiotis, Luxton, Mount, Mudge, Noble, Phoon, Ritchie, Ryan, Suranyi, Rosenkranz, Kronbichler, Demoulin, Tags: Open access, ARD, Vasculitis Source Type: research
Card9/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis
Conclusions
These data reveal a novel neutrophil-intrinsic role for Card9 in arthritogenic Th17 responses and AS pathogenesis. These data provide valuable utility in our future understanding of CARD9-specific mechanisms in spondyloarthritis . (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Rosenzweig, H. L., Vance, E. E., Asare-Konadu, K., Koney, K. V., Lee, E. J., Deodhar, A. A., Sen, R., Caplan, L., Napier, R. J. Tags: Open access, ARD, Spondyloarthritis Source Type: research
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
Conclusions
At Week 52, dual inhibition of IL-17A and IL-17F with BKZ resulted in sustained efficacy across the axSpA spectrum; the safety profile was consistent with the known safety of BKZ.
Trial registration number
NCT03928704; NCT03928743. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Baraliakos, X., Deodhar, A., van der Heijde, D., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Fleurinck, C., Ellis, A. M., Vaux, T., Shepherd-Smith, J., Marten, A., Gensler, L. S. Tags: Open access, ARD, Spondyloarthritis Source Type: research
Specific descriptions of axial involvement are associated with radiographic damage development after 2 years in psoriatic arthritis patients
Conclusions
The likelihood of syndesmophyte formation in PsA is low. The probability of developing syndesmophytes is much higher when axial involvement is determined radiographically rather than clinically, particularly in the context of high CRP. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: de Hooge, M., Ischenko, A., Steinfeld, S., Nzeusseu, A., Elewaut, D., Lories, R., Van den Bosch, F., De Vlam, K. Tags: Open access, ARD, Psoriatic arthritis Source Type: research
